Background: Depot medroxyprogesterone acetate (DMPA), a long-acting contraceptive, has many advantages
over other hormonal contraceptives. However, its major discontinuance reason is bleeding disorders.
Our aim was to study bleeding complications of DMPA when used as a contraceptive in the Ardabil district and a clinical trial of low-dose oral contraceptive (LD-OC) pills in controlling these complications.
Material/Methods: All 917 women referred to Ardabil’s health centers to have a DMPA injection for the fi rst time were entered into a longitudinal study. Those complaining of menstrual cessation were entered into a double-blinded randomized clinical trial. Data were collected by means of nine questionnaires, seven
of which were used for descriptive purposes and two for clinical trial study. The data were analyzed
with the SPSS statistical package.
Results: Those DMPA users with a cesarean section history had a higher chance of bleeding complications.
Four hundred forty-four of the 917 women receiving the injection discontinued using it before the
end of the study period. The main reason for discontinuation (in 70%) was irregular menstrual
bleedings and menstrual cessation. In the clinical trial of women with bleeding cessation, 70% of
those receiving the LD-OC pill experienced menstrual bleedings again, compared with only 22.7%
in the placebo group. The discontinuation rate in the drug group was lower than in the placebo
group as well (,i>p

Keywords: Contraceptives, Oral - adverse effects, Amenorrhea - drug therapy, Dose-Response Relationship, Drug, Medroxyprogesterone Acetate - adverse effects, Menstruation - drug effects, Patient Compliance